Immune checkpoint inhibitors are an emerging and hopeful therapeutic option for a variety of tumours, and several clinical trials are showing good efficacy and tolerance to PD-1 checkpoint inhibitors in locally advanced HNSCC [14,15,16]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.